New Phase 2 trial data show benefits of elafibranor for PSC
Daily treatment with Ipsen’s elafibranor safely and effectively eases itching, stabilizes liver scarring, and reduces liver damage biomarkers in adults with primary sclerosing…
Cholangitis
High IgG levels at diagnosis tied to worse PBC outcomes: Study
High blood levels of the antibody immunoglobulin G, or IgG, at diagnosis are linked to a more severe disease course among people with primary…
American Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
Focus of World Liver Day this April 19 is role of diet in liver health
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
Scotland to cover Iqirvo for eligible primary biliary cholangitis patients
The Scottish Medicines Consortium (SMC) has agreed that Ipsen’s Iqirvo (elafibranor) be covered by the country’s public National Health Service (NHS), making the therapy…
Nebokitug shows sustained benefits for moderate, advanced PSC
A year of treatment with Chemomab Therapeutics’s candidate nebokitug reduces key disease biomarkers and the occurrence of clinical events that reflect disease progression among…
2nd-line PBC treatment options call for personalized care: Analysis
Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi…
Trial testing golexanolone as PBC treatment delayed
A Phase 1b/2 trial testing Umecrine Cognition’s golexanolone in primary biliary cholangitis (PBC) patients with cognitive symptoms and fatigue has been delayed due to…
Canadian scientists given grant to advance ways of treating PSC
Conscience, a Canadian nonprofit, has awarded CA$461,241 (nearly $320,000) to a research project aiming to provide preclinical data that could lead to new approaches…
How I advocated for my brother before and after his PSC diagnosis
“I can’t explain why, but I don’t feel well,” my younger brother, Osari, said. He was 32 years old at the time. That statement was…
